1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,268 | 0,284 | 13:03 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT APPROVAL OF ENVIRONMENTAL IMPACT REPORT FOR LANGHUA PHARMACEUTICAL | 1 | HKEx | ||
| 05.01. | VIVA BIOTECH (01873): UPDATE ANNOUNCEMENT REGARDING DEEMED DISPOSAL AND DISPOSAL OF EQUITY INTEREST IN VIVA SHANGHAI | - | HKEx | ||
| 29.12.25 | Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities | 222 | PR Newswire | SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader... ► Artikel lesen | |
| 15.12.25 | Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. | 405 | PR Newswire | STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which... ► Artikel lesen | |
| 02.12.25 | VIVA BIOTECH (01873): GRANT OF SHARE OPTIONS | 5 | HKEx | ||
| 29.09.25 | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 281 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen | |
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 25.09.25 | VIVA BIOTECH (01873): INTERIM REPORT 2025 | - | HKEx | ||
| 02.09.25 | Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights | 272 | PR Newswire | SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge... ► Artikel lesen | |
| 28.08.25 | Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth | 431 | PR Newswire | Financial Highlights for Interim Results ended 30 June 2025Revenue reached RMB831.9 millionGross profit amounted to RMB339.4 millionGross profit margin was 40.8%, an increase of 6.3 percentage... ► Artikel lesen | |
| 28.08.25 | VIVA BIOTECH (01873): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 2 | HKEx | ||
| 18.08.25 | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 2 | HKEx | ||
| 15.05.25 | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 384 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen | |
| 28.03.25 | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 421 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03.25 | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 228 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,894 | -0,36 % | Wochenend-Check: Valneva - Montag könnte die Entscheidung bringen | ||
| NOVONESIS | 51,72 | +0,27 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| GENMAB | 272,10 | -1,09 % | EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) | ||
| ARBUTUS BIOPHARMA | 3,466 | 0,00 % | Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 286,00 | 0,00 % | BEONE MEDICINES (06160): GRANT OF RESTRICTED SHARE UNITS | ||
| SINO BIOPHARM | 0,719 | +1,90 % | SINO BIOPHARM's TQA3605 'Core Protein Allosteric Modulator' for Chronic Hepatitis B Achieves Primary Endpoint in Phase II Clinical Trials | ||
| VERICEL | 30,400 | +1,33 % | Vericel Corporation: Vericel Announces Preliminary 2025 Financial Results and Business Updates | Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| MOLECULIN BIOTECH | 4,230 | -0,47 % | Moleculin Biotech, Inc.: Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects | - Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials - This next-generation anthracycline demonstrates safety and promising early activity in treating multiple... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 9,570 | -0,93 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,425 | -11,64 % | BioTech und LifeSciences stark im Aufwind und nun auch noch Mercosur! Bayer, MustGrow, Novo Nordisk und BioNxt im Fokus | Das Börsenjahr 2026 hält für die Anleger einige Überraschungen parat. Denn neben einer schnellen Lösung im Grönland-Streit, macht sich auch das Handelsabkommen Mercosur mit einigen Südamerika-Staaten... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,294 | -3,29 % | BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI | NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines... ► Artikel lesen | |
| ZAI LAB LTD ADR | 14,000 | 0,00 % | UBS Sees Zai Lab (ZLAB) as a Rising Global Biopharma Platform | ||
| REGENXBIO | 9,400 | -0,53 % | Regenerative Medizin im Aufschwung: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Strategien | ||
| AKEBIA | 1,181 | -1,09 % | Akebia Therapeutics, Inc. - 8-K, Current Report | ||
| ZEVRA THERAPEUTICS | 7,550 | -0,66 % | Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) | CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living... ► Artikel lesen |
Das Unternehmen VIVA BIOTECH HOLDINGS kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,012 (-4,29 %) liegt der Kurs bei 0,268 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.